Prior vaccinations improve immunogenicity of inactivated influenza vaccine in young children aged 6 months to 3 years: A cohort study.

Medicine (Baltimore)

Department of Public Health, Osaka City University Graduate School of Medicine; Research Center for Infectious Disease Sciences, Osaka City University Graduate School of Medicine, Osaka SOUSEIKAI Clinical Epidemiology Research Center College of Healthcare Management, Fukuoka SOUSEIKAI Sumida Hospital, Tokyo SOUSEIKAI SOUSEIKAI, PS Clinic Takasaki Pediatric Clinic Shindo Children's Clinic Yokoyama Pediatric Clinic Yamashita Pediatric Clinic Shibao Clinic, Fukuoka SOUSEIKAI Dodo Clinic, Tokyo, Japan.

Published: July 2018

In young children, infrequent antigen exposure, which is partly characterized by fewer vaccinations, may be a factor impairing the immunogenicity of inactivated influenza vaccine.We assessed the effects of prior vaccinations on age-specific immune responses in Japanese children aged 6 months to 3 years, using data from a cohort study with 266 children who had received 2 doses (0.25 mL/dose for < 3 years old, 0.5 mL/dose for 3 years old) in the 2006/2007 season. Serological measures, primarily seroprotection rates, between previously vaccinated and vaccine-naïve children were compared within 1-year age strata. The seroprotection rate was defined in 2 ways as the proportion of subjects who achieved an antibody titer of 1:40 or 1:160. Multivariate logistic regression was also performed to estimate the independent effect of prior vaccination on seroprotection rate.After the first dose, seroprotection rates with the threshold of 1:40 in vaccine-naïve 1-year-olds remained low (28% for AH1, 26% for AH3, 2% for B), similar to those of 0-year-olds. In contrast, seroprotection rates in previously vaccinated 1-year-olds (77% for AH1, 86% for AH3, 18% for B) were significantly higher than those in vaccine-naïve 1-year-olds. These seroprotection rates for AH1 and AH3 were comparable with those in previously vaccinated 2- and 3-year-olds. Although seroprotection rates for B remained low in every age stratum even after the second dose, seroprotection rate in previously vaccinated 1-year-olds (50%) was similar to that in 3-year-olds. After adjustment for age, baseline antibody titer and experience of acute febrile respiratory illness in the preceding season, odds ratios showed a significant independent positive effect of prior vaccination on seroprotection rate for every strain. After the seroprotection threshold was changed from 1:40 to 1:160, the results of the effects of prior vaccinations on immunogenicity were similar or became more evident, which demonstrate the robustness of our findings.Our study found that prior vaccinations improved poor immunogenicity among young children, especially in 1-year-olds.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6086539PMC
http://dx.doi.org/10.1097/MD.0000000000011551DOI Listing

Publication Analysis

Top Keywords

seroprotection rates
20
prior vaccinations
16
young children
12
seroprotection rate
12
seroprotection
10
immunogenicity inactivated
8
inactivated influenza
8
children aged
8
aged months
8
months years
8

Similar Publications

Background: Vaccine co-administration can increase vaccination coverage. We assessed the safety, reactogenicity, and immunogenicity of concomitant administration of Ad26.COV2.

View Article and Find Full Text PDF

Background And Objectives: Hepatitis B vaccination (HBV) requires 6 months to complete and is recommended for patients with multiple sclerosis (PWMS), particularly those who are candidates for anti-CD20 therapy. However, limited data exist on HBV immunogenicity in PWMS receiving disease-modifying therapies (DMTs) and the impact of starting anti-CD20 therapy during immunization. We aimed to evaluate HBV immunogenicity in PWMS starting anti-CD20 therapy during vaccination, focusing on the number of doses received before anti-CD20 initiation.

View Article and Find Full Text PDF

Introduction/objectives: The study aimed to determine whether in children with newly diagnosed juvenile idiopathic arthritis (JIA) hepatitis B surface antibody (anti-HBs) differs from healthy children and to see whether the revaccination is safe and effective under JIA treatment.

Methods: Patients who were followed up with a diagnosis of JIA between January 2020 and February 2024 were included. The control group consisted of healthy children matched for age and gender.

View Article and Find Full Text PDF

This study aimed to evaluate the impact of Thailand's hepatitis B virus (HBV) National Program Immunization (NPI), 32 years post-implementation, on infection rates and immunity in various age groups. A cross-sectional study involved 6,068 participants aged 6 months to 80 years from four regions in Thailand. Blood samples were tested for HBsAg, anti-HBs, and anti-HBc using a chemiluminescent immunoassay.

View Article and Find Full Text PDF

Objective: Children with Chronic Kidney Disease (CKD) are at increased risk for vaccine-preventable diseases. The primary objective of the study was to estimate IgG antibody titers against measles, mumps, and rubella (MMR) in children with CKD and healthy controls who were previously immunized with measles/ MMR vaccine.

Methods: This case control study was conducted between January 2019 and January 2020.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!